High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL). This was a prospective phase II trial of rituximab plus fractionated cyclopho...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 23; číslo 28; s. 7013
Hlavní autoři:	Romaguera, Jorge E, Fayad, Luis, Rodriguez, Maria A, Broglio, Kristine R, Hagemeister, Frederick B, Pro, Barbara, McLaughlin, Peter, Younes, Anas, Samaniego, Felipe, Goy, Andre, Sarris, Andreas H, Dang, Nam H, Wang, Michael, Beasley, Virginia, Medeiros, L Jeffrey, Katz, Ruth L, Gagneja, Harish, Samuels, Barry I, Smith, Terry L, Cabanillas, Fernando F
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.10.2005
Témata:	Administration, Oral Adult Age Factors Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - administration & dosage Dexamethasone - administration & dosage Disease-Free Survival Doxorubicin - administration & dosage Drug Administration Schedule Female Humans Infusions, Intravenous Lymphoma, Mantle-Cell - drug therapy Lymphoma, Mantle-Cell - pathology Male Middle Aged Rituximab Treatment Outcome Vincristine - administration & dosage
ISSN:	0732-183X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!